Your browser doesn't support javascript.
loading
Histamine and Delirium: Current Opinion.
Chazot, Paul L; Johnston, Laura; Mcauley, Edel; Bonner, Stephen.
Afiliação
  • Chazot PL; Department of Biosciences, Durham University, Durham, United Kingdom.
  • Johnston L; Department of Biosciences, Durham University, Durham, United Kingdom.
  • Mcauley E; Intensive Care, South Tees Hospitals NHS Foundation Trust, The James Cook University Hospital, Middlesbrough, United Kingdom.
  • Bonner S; Intensive Care, South Tees Hospitals NHS Foundation Trust, The James Cook University Hospital, Middlesbrough, United Kingdom.
Front Pharmacol ; 10: 299, 2019.
Article em En | MEDLINE | ID: mdl-31024298
Delirium is a very common, but refractory clinical state, notably present in intensive care and in the growing aging community. It is characterized by fluctuating disturbances in a number of key behavioral features, namely cognition, mood, attention, arousal, and self-awareness. Histamine is arguably the most pleotropic neurotransmitter in the human brain, and this review provides a rationale, and proposes that this neuroactive amine plays a role in modulating the characteristic features of delirium. While centrally permeable H1 and H2 histamine receptor antagonists have pro-delirium potential, we propose that centrally permeable H3 histamine receptor antagonists may provide an exciting new strategy to combat delirium. The Histamine H4 receptor may also have an indirect inflammatory neuroglial role which requires further exploration.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Pharmacol Ano de publicação: 2019 Tipo de documento: Article